Vertex Pharmaceuticals

Historical price data

Vertex Pharmaceuticals is a premier biotechnology company that has revolutionized treatment for cystic fibrosis with its portfolio of CFTR modulators, generating billions in annual revenue. The company has successfully expanded beyond CF into gene editing with CTX001 for sickle cell disease and beta thalassemia, and is advancing programs in pain, diabetes, and other serious diseases. With a strong commercial franchise and robust pipeline, Vertex represents one of the most successful biotech companies in translating scientific innovation into life-changing medicines.

Vertex specializes in structure-based drug design and precision medicine, developing small molecule modulators and advancing gene editing technologies through CRISPR/Cas9 approaches and cell therapies.

264 drugs in pipeline, 93 in Phase 3

Vertex maintains a dominant position in cystic fibrosis with limited direct competition, while facing emerging competition in gene editing from companies like bluebird bio and in pain management from established pharmaceutical companies, though its novel mechanisms provide differentiation opportunities.